Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more
Cellectis SA (CLLS) - Net Assets
Latest net assets as of September 2025: $100.48 Million USD
Based on the latest financial reports, Cellectis SA (CLLS) has net assets worth $100.48 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($343.05 Million) and total liabilities ($242.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $100.48 Million |
| % of Total Assets | 29.29% |
| Annual Growth Rate | 6.69% |
| 5-Year Change | -57.57% |
| 10-Year Change | -54.54% |
| Growth Volatility | 243.25 |
Cellectis SA - Net Assets Trend (2007–2024)
This chart illustrates how Cellectis SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cellectis SA (2007–2024)
The table below shows the annual net assets of Cellectis SA from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $131.03 Million | +54.71% |
| 2023-12-31 | $84.69 Million | -32.75% |
| 2022-12-31 | $125.94 Million | -46.74% |
| 2021-12-31 | $236.47 Million | -23.43% |
| 2020-12-31 | $308.85 Million | -13.12% |
| 2019-12-31 | $355.47 Million | -21.05% |
| 2018-12-31 | $450.27 Million | +57.49% |
| 2017-12-31 | $285.90 Million | +4.33% |
| 2016-12-31 | $274.05 Million | -4.92% |
| 2015-12-31 | $288.22 Million | +298.17% |
| 2014-12-31 | $72.39 Million | +988.46% |
| 2013-12-31 | $6.65 Million | -91.86% |
| 2012-12-31 | $81.69 Million | +120.64% |
| 2011-12-31 | $37.02 Million | -26.15% |
| 2010-12-31 | $50.13 Million | -31.54% |
| 2009-12-31 | $73.22 Million | +58.45% |
| 2008-12-31 | $46.21 Million | +6.13% |
| 2007-12-31 | $43.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellectis SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32960700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.89 Million | 4.49% |
| Other Comprehensive Income | $-39.54 Million | -30.17% |
| Other Components | $494.29 Million | 377.22% |
| Total Equity | $131.03 Million | 100.00% |
Cellectis SA Competitors by Market Cap
The table below lists competitors of Cellectis SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ELIXIRR INTL LS -00005
F:54K
|
$161.06 Million |
|
Greaves Cotton Limited
NSE:GREAVESCOT
|
$161.10 Million |
|
Eastern Media International Corp
TW:2614
|
$161.17 Million |
|
Jiangsu Daybright Intelligent Electric Co Ltd
SHE:300670
|
$161.18 Million |
|
Beijing North Star Company Limited
PINK:BEIJF
|
$161.03 Million |
|
Omai Gold Mines Corp
OTCQB:OMGGF
|
$160.98 Million |
|
Compugen
NASDAQ:CGEN
|
$160.97 Million |
|
CWB Automotive Electronics Co Ltd
SHG:605005
|
$160.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellectis SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,695,000 to 131,033,000, a change of 46,338,000 (54.7%).
- Net loss of 36,761,000 reduced equity.
- New share issuances of 82,822,000 increased equity.
- Other comprehensive income decreased equity by 2,847,000.
- Other factors increased equity by 3,124,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.76 Million | -28.05% |
| Share Issuances | $82.82 Million | +63.21% |
| Other Comprehensive Income | $-2.85 Million | -2.17% |
| Other Changes | $3.12 Million | +2.38% |
| Total Change | $- | 54.71% |
Book Value vs Market Value Analysis
This analysis compares Cellectis SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.13x to 2.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $3.08 | $3.47 | x |
| 2008-12-31 | $3.27 | $3.47 | x |
| 2009-12-31 | $5.18 | $3.47 | x |
| 2010-12-31 | $3.55 | $3.47 | x |
| 2011-12-31 | $2.62 | $3.47 | x |
| 2012-12-31 | $3.96 | $3.47 | x |
| 2013-12-31 | $0.34 | $3.47 | x |
| 2014-12-31 | $2.82 | $3.47 | x |
| 2015-12-31 | $8.33 | $3.47 | x |
| 2016-12-31 | $7.60 | $3.47 | x |
| 2017-12-31 | $7.48 | $3.47 | x |
| 2018-12-31 | $10.04 | $3.47 | x |
| 2019-12-31 | $7.42 | $3.47 | x |
| 2020-12-31 | $6.68 | $3.47 | x |
| 2021-12-31 | $4.94 | $3.47 | x |
| 2022-12-31 | $2.59 | $3.47 | x |
| 2023-12-31 | $1.49 | $3.47 | x |
| 2024-12-31 | $1.45 | $3.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellectis SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88.57%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 2.93x
- Recent ROE (-28.05%) is above the historical average (-99.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.01% | -106.22% | 0.08x | 1.24x | $-8.71 Million |
| 2008 | 0.40% | 1.25% | 0.24x | 1.32x | $-4.44 Million |
| 2009 | -7.54% | -31.87% | 0.19x | 1.25x | $-12.84 Million |
| 2010 | -21.39% | -51.11% | 0.30x | 1.38x | $-15.74 Million |
| 2011 | -83.45% | -149.05% | 0.16x | 3.56x | $-34.60 Million |
| 2012 | -37.32% | -105.89% | 0.24x | 1.46x | $-37.34 Million |
| 2013 | -1212.90% | -369.38% | 0.52x | 6.35x | $-84.97 Million |
| 2014 | 0.03% | 0.09% | 0.16x | 2.26x | $-7.37 Million |
| 2015 | -7.81% | -40.81% | 0.15x | 1.30x | $-51.20 Million |
| 2016 | -23.48% | -150.10% | 0.13x | 1.21x | $-91.14 Million |
| 2017 | -37.25% | -394.51% | 0.08x | 1.25x | $-126.05 Million |
| 2018 | -19.23% | -618.12% | 0.03x | 1.22x | $-119.62 Million |
| 2019 | -28.78% | -597.01% | 0.03x | 1.48x | $-122.20 Million |
| 2020 | -25.57% | -98.14% | 0.16x | 1.65x | $-100.95 Million |
| 2021 | -38.99% | -116.68% | 0.19x | 1.73x | $-108.41 Million |
| 2022 | -83.66% | -514.78% | 0.07x | 2.21x | $-110.48 Million |
| 2023 | -119.32% | -13385.30% | 0.00x | 3.95x | $-109.53 Million |
| 2024 | -28.05% | -88.57% | 0.11x | 2.93x | $-49.86 Million |
Industry Comparison
This section compares Cellectis SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellectis SA (CLLS) | $100.48 Million | -10.01% | 2.41x | $161.06 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |